RxDoctor Payments Data

Fred Nagel, MD

Family Medicine · Maumelle, ARNPI 1922016674

Payments from drug & device makers

$7,639in general payments, 2019–2025

Across 485 payments — averaging $15.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$850
  • Boehringer Ingelheim$724
  • Pfizer$717
  • AbbVie$679
  • Lilly USA, LLC$519
  • Bayer$436
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,602100%
  • Education$370%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,639 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$133,553
Medicare patients
424
Services billed
10,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$126,254
JardianceEmpagliflozin143$120,727
EliquisApixaban125$87,218
JanuviaSitagliptin Phosphate98$75,850
FarxigaDapagliflozin Propanediol91$74,288
TrulicityDulaglutide56$55,745
Tresiba Flextouch U-200Insulin Degludec60$42,457
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$41,889
XifaxanRifaximin11$36,128
MounjaroTirzepatide34$32,394
Tresiba Flextouch U-100Insulin Degludec44$25,575
LinzessLinaclotide31$21,537
MyrbetriqMirabegron34$19,320
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$19,063
XareltoRivaroxaban12$16,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$724$134,722161 claims
Novo NordiskOzempic$368$126,254118 claims
PfizerEliquis, Premarin$717$91,124140 claims
MerckJanuvia, Janumet$354$89,153114 claims
Lilly USA, LLCTrulicity, Mounjaro$519$88,13990 claims
AstraZenecaFarxiga, Symbicort$850$80,853118 claims
GSKTrelegy Ellipta, Breo Ellipta$184$50,99076 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$317$36,12811 claims
AbbVieLinzess, Savella$679$33,74645 claims
Astellas Pharma US IncMyrbetriq$321$19,32034 claims
Johnson & JohnsonXarelto$162$16,67612 claims
NovartisEntresto$17$13,43514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Maumelle

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →